Bevacizumab (Avastin), a synthetic monoclonal antibody used against vascular endothelial growth factor (anti-VEGF), was reported to limit scar formation following glaucoma filtration surgery and to effectively decrease patients’ IOP (7,8). The gene discussed is VEGFA; the disease is glaucoma.